Clinical Trial: NCT04533451
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Alliance for Clinical Trials in Oncology |
| Information Provided By: | Alliance for Clinical Trials in Oncology |
| Last Update Posted: | 2026-10-08 |
Study Overview
Brief Summary
This study evaluates the side effects of pembrolizumab with or without chemotherapy in treating patients with stage IV non-small cell lung cancer that has come back after a period of improvement (recurrent) and may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with or without chemotherapy may shrink the tumor in older patients with non-small cell lung cancer.
Official Title
Conditions
Intervention / Treatment
- Drug: Pembrolizumab
- Drug: Pemetrexed
- Drug: Carboplatin
- Other: Comprehensive Geriatric Assessment
- Other: Questionnaire Administration
- Other: Quality-of-Life Assessment
Other Study ID Numbers
- A171901
- NCI-2020-00544
- UG1CA189823
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Alliance for Clinical Trials in Oncology |
| Information Provided By: | Alliance for Clinical Trials in Oncology |
| Last Update Posted: | 2026-10-08 |
Study Overview
Brief Summary
This study evaluates the side effects of pembrolizumab with or without chemotherapy in treating patients with stage IV non-small cell lung cancer that has come back after a period of improvement (recurrent) and may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with or without chemotherapy may shrink the tumor in older patients with non-small cell lung cancer.
Official Title
Conditions
Intervention / Treatment
- Drug: Pembrolizumab
- Drug: Pemetrexed
- Drug: Carboplatin
- Other: Comprehensive Geriatric Assessment
- Other: Questionnaire Administration
- Other: Quality-of-Life Assessment
Other Study ID Numbers
- A171901
- NCI-2020-00544
- UG1CA189823